Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier 44-page report, we printed it out and...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value of award to GeoVax and its CRO partner total approximately $367-388 million
BARDA-funded...
GeoVax Receives Massive $300+ Million BARDA Project NextGen Award!
Are we happy, you betcha!
We just got back from St Croix where the team from the Beverage Stock Review visited the Mutiny Island Vodka...
GeoVax (GOVX) Research Reports Archive
Research Report Archive
Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research. Jason Kolbert at Dawson James Securities. Vernon...
GeoVax to Provide Corporate Update on Tuesday May 14, 2024.
Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market cap, addressing...
NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...
Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is gone -...
COVID-19 Immunity From mRNA Booster Does Not Last Very Long.
Study finds that the median length for the antibody half-life immune response was 63 days for the primary series, and increased to 115 days...
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we follow, shows a spike in either...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
We're adding Citius Pharma to the Watch...
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class...